Resource Hub
VIRTUAL TOUR
CONTACT US
Our Company
Investors
Services
Our Responsibility
Careers
Our Company
Investors
Services
Our Responsibility
Careers
© 2024 Aragen Bioscience. All rights reserved
Back
About Us
Our Journey
Leadership
Scientific and BD Team
Aragen Advantage
Investors
Global Locations
Media & Events
Recognitions
Disclosures under Regulation 62 of the LODR
Corporate Governance
Small Molecules
Large Molecules (Biologics)
Discovery
Aragen Integrated Drug Discovery (AIDD)
Integrated Drug Discovery
Chemistry
Biology
Safety Assessment
Development & Manufacturing
Drug Substance - new
Drug Substance
Drug Product
Analytical Development
Performance Chemicals
Custom Chemical Synthesis
Commercial Manufacturing
Discovery
Integrated Discovery
Molecular Biology
Antibody Discovery
Protein Sciences
Cell Line Development
Biology
Development & Manufacturing
Process Research & Development
Bioproduction
Developability & Analytics
GMP Manufacturing
EHS & Sustainability
Strategic Supply Chain Management
Quality
IP Protection & Data Security
Employee Welfare
Corporate Social Responsibility
Corporate Governance
Working at Aragen
Career Opportunities
Meet Our People
Caution Notice
Close Search
Search
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
GET IN TOUCH
Back to Resources
Case Studies
Filter by Science
All
All
Analytical
Biologics
Biology
Chemistry
Development
Ecotoxicology
Formulations BU
Intox
Manufacturing
NBEs Intox
PCET
SAS/Toxicology
Redefine In silico Predictions with High-throughput LC-MS/MS LogD Analysis
Unravelling Immunological Depths: Exploring Oxazolone-induced Delayed-Type Hypersensitivity Model
Unlocking Insights: A Translational Mouse Model for Non-Genetic Heterotopic Ossification
A Preclinical Efficacy Study using Diet induced Obesity Mice Model
Designing an optimal and scalable protocol for formulating a 40% emulsifiable concentrate for a systemic insecticide
Developing a thermodynamically stable microemulsion with fine droplet size for delivering a highly lipophilic drug with limited intestinal permeability
Elevating Purity Levels: Racemizing Pharmaceutical Products in Advanced Flow Microreactors
Modelling Targeted Protein Degraders (TPDs) Utilizing Computational and Medicinal Chemistry Approaches
A robust and scalable strategy to develop monodisperse Nanosuspension formulation for a poorly soluble drug substance
A robust and scalable strategy to develop amorphous solid dispersion formulation for a poorly soluble drug substance
Comprehensive Preclinical Development Program for a COVID mRNA Vaccine
Expression, in vivo Maturation and Tag-less Purification of a Recombinant Protein
Alcoholic Steatohepatitis Model – CDAHFD
Consistency of Bleomycin-induced pulmonary fibrosis
Pro-inflammatory chemokines measured in bronchoalveolar lavage fluid (BALF)
Consistency of fibrotic induction in lungs from multiple studies
Non-Alcoholic Steatohepatitis Model
Treatment of CDAHFD-induced NASH mice with Elafibranor
Showing the readouts using the above-mentioned protocol
CS – Oncology 1
CS – Oncology 2
CS – Oncology 3
CS – Oncology 4
An optimal upstream process development approach to increase the titers of the monoclonal antibodies (mAbs)
Enabling Formulation Development for Toxicology Studies for a New Chemical Entity
Physical Form Selection of a Small Molecule
Learn more about our end-to-end capabilities
×
Contact An Expert Today!
Contact Us
+
+
Back to Resources
